Practical AI Learning the language of life
May 3, 2022
Sean McClain, Founder and CEO of Absci, and Joshua Meier, Lead AI Scientist at Absci, share insights on how AI is revolutionizing drug discovery. They discuss the transition from traditional methods to AI-driven techniques, emphasizing the potential of digital twins and mRNA technology. The duo explores how AI analyzes biological data for personalized medicine and enhances clinical trials. With promises of more efficient drug development, their vision showcases a future where AI solutions lead to innovative healthcare transformations.
AI Snips
Chapters
Transcript
Episode notes
Traditional Drug Discovery
- Traditional drug discovery is an archaic process relying on animal testing or cell displays.
- It involves tedious development for manufacturability and developability, taking years and billions of dollars.
AI's Past Failures in Biotech
- AI's previous failures in biotech were due to a lack of quality biological data.
- Companies like Absci are now generating the high-throughput, high-quality data needed to train effective AI models.
AI-Driven Drug Design
- AI can shift drug discovery towards data-driven design, increasing the likelihood of success.
- This approach focuses on biophysics and molecular interactions, leading to more effective drug candidates.